FDA approves drug for rare condition that triggers intense pain from light exposure
Five years after EU regulators approved a therapy to treat a rare inherited metabolic condition that causes extreme sensitivity to light, the FDA has endorsed the treatment — marking the first-ever approval for patients with erythropoietic protoporphyria (EPP) in the United States.
The therapy, which is administered via an implant inserted subcutaneously, was developed by Australian drug maker Clinuvel Pharmaceuticals and is sold as Scenesse.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.